Klin Onkol 2000; 13(3): 83-87.
Abstract: Purpose: This study was undertaken to determne the activity and toxicity of regional chemotherapy using an isolated thoracic perfusion (ITP) technique as second line treatment in advanced Non Small Cell Lung Cancer (NSCLC) patients. Patients and methods: 30 patients with relapsed NSCLC defined to thoracic region entered onto the study were to receive regional chemotherapy using ITP as application form. All 30 patients had been pretreated with some form of chemotherapy, surgery and/ or radiotherapy. Two different citostatic regimens has been used: group A: regional chemotherapy alone using Mitomycin 10 mg/m2, Aclarubicin 22 mg/m2 and Melphalan 10mg/m2 during ITP, group B: regional chemotherapy using Mitomycin 10 mg/m2, Navelbine'25 mg/m and Cis-Platin 30 mg/m2 during ITP on day 1 plus low dose systemic chemotherapy (5-Aoururaci1250 mg/m2, Cis-Platin 20 mg/m2 given as continuous infusion over 24 hours, day 1-4. There were 15 patients in each group of chemotherapy; baseline data were comparable between both groups. Response, toxicity and survival data were noted. Results: All 30 patients were assessable for toxicity, response and survival. There were 6/15 responses in group A ( CR.: 1; PR 5; RR 40 %) and 8/15 in group B (CR.: O; PR 8; RR 53.3 %). Side ffects were transient and acceptable in both groups. No treatment elated death was observed. Median survival was 16 months in group A and 22 months in group B.1-year survival rate was 53.3 % in group A and 82.5 % in group B. Differences were not statistical significant. Conclusion: Compared to standard systemic chemotherapeutic regimens regional chemotherapy using an ITP application form is highly active in relapsing advanced NSCLC with an encouraging survival outcome. In this small group of patients response rates as well as survival rates could be doubled with an advantage to a combined regional plus systemic application form.
